Skip to main content
. Author manuscript; available in PMC: 2013 Aug 23.
Published in final edited form as: Am Heart J. 2011 May;161(5):972–978. doi: 10.1016/j.ahj.2011.01.017

Figure 2.

Figure 2

Effect of darapladib on Lp-PLA2 in patients with and without PAD. The results are presented as geometric means with 95% CI. Darapladib produced highly significant inhibition of Lp-PLA2 activity when compared with placebo at weeks 4 and 12 (P < .01) in patients with and without PAD.